Kwabena Ayesu
Expertise in
1
conditions

Dr. Kwabena Ayesu

Internal Medicine
Patrick M. Gill, MD - Internal Medicine
21 W. Columbia St., 
Orlando, FL 
44 Years of Experience
Expertise in
1
conditions
Patrick M. Gill, MD - Internal Medicine
21 W. Columbia St., 
Orlando, FL 

Overview

Kwabena Ayesu is a primary care provider, practicing in Internal Medicine in Orlando, Florida. He has been practicing medicine for over 44 years.

Dr. Ayesu is highly rated in 1 condition, according to our data. His clinical expertise encompasses Ludwig Angina, Prothrombin Deficiency, Sepsis, Gastrostomy, and Endoscopy.

Dr. Ayesu is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 21 clinical trials.

Graduate Year

1982

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

Orlando Health

Languages Spoken

English
German
Mandarin

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Patrick M. Gill, MD - Internal Medicine
21 W. Columbia St., Orlando, FL 32806
Other Locations
Orlando Health Physician Associates - Downtown Orlando
86 W. Underwood St., Suite 102, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
View 9 Less Clinical Trials

9 Total Publications

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo-Controlled Phase 3 Trials.
Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo-Controlled Phase 3 Trials.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 24, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Richard E. Pratley
Internal Medicine
Expertise in
9
conditions
Dr. Richard E. Pratley
Internal Medicine

AdventHealth Medical Group Diabetes And Endocrinology At Orlando

2415 N Orange Ave, Suite 502, 
Orlando, FL 
 (3.2 miles away)
407-303-2801
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Pratley is a primary care provider, practicing in Internal Medicine in Orlando, Florida. Dr. Pratley is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Low Blood Sugar, Type 1 Diabetes (T1D), and Maturity Onset Diabetes of the Young. Dr. Pratley is currently accepting new patients.

Expertise in
36
conditions
Dr. Dinesh Khanna
Internal Medicine
Expertise in
36
conditions
Dr. Dinesh Khanna
Internal Medicine
Before you request

Premier Medical Associates

1580 Santa Barbara Blvd Ste C, 
The Villages, FL 
 (42.2 miles away)
352-259-2159
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Dinesh Khanna is a primary care provider, practicing in Internal Medicine in The Villages, Florida. Dr. Khanna is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Lung Transplant. Dr. Khanna is board certified in American Board Of Internal Medicine. Dr. Khanna is currently accepting new patients.

Expertise in
15
conditions
Dr. Adriana Otto
Internal Medicine
Expertise in
15
conditions
Dr. Adriana Otto
Internal Medicine

Orange Primary Care P.A.

1400 S Orlando Ave Ste 205, 
Winter Park, FL 
 (5.1 miles away)
321-972-8274
Languages Spoken:
English
See accepted insurances

Adriana Otto is a primary care provider, practicing in Internal Medicine in Winter Park, Florida. Dr. Otto is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Mitral Stenosis, Heart Tumor, Atrial Myxoma, Heart Valve Repair, and Aortic Valve Replacement.

Frequently Asked Questions about Dr. Kwabena Ayesu

How do I make an appointment with Dr. Kwabena Ayesu?

You can book an appointment with Dr. Kwabena Ayesu by calling their office at 321-841-3581. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kwabena Ayesu a top-rated expert for Ludwig Angina?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kwabena Ayesu is classified as an Advanced expert for Ludwig Angina, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kwabena Ayesu specialize in?

While Dr. Kwabena Ayesu is a Internal Medicine, they have specific expertise in Ludwig Angina, Prothrombin Deficiency, and Sepsis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Kwabena Ayesu participate in research or clinical trials?

Yes. Dr. Kwabena Ayesu has published 9 articles and abstracts on conditions like Ludwig Angina. You can view a list of Dr. Kwabena Ayesu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kwabena Ayesu accept my insurance?

Dr. Kwabena Ayesu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 321-841-3581 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ayesu's expertise for a condition
ConditionClose
      View All 52 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile